All In Biotech

Drug Trial Radar · NCT06756932

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 4, 2025

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Conditions

  • Hormone-receptor-positive Breast Cancer
  • HER2-negative Breast Cancer
  • Metastatic Breast Cancer

Interventions

  • BGB-21447Drug

    Administered orally.

  • FulvestrantDrug

    Administered via intramuscular injection.

  • BGB-43395Drug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 6 months
  2. Part 1: Recommended Dose for Expansion (RDFE) of BGB-21447 in combination with fulvestrant and in combination with fulvestrant and BGB-43395Time frame: From first dose of the study drug(s) to 30 days after the last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 6 to 9 months
  3. Part 2: Objective Response Rate (ORR)Time frame: Approximately 12 months

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Saint Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia · Terminated

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Sunshine Coast University Private Hospital

    Birtinya, Queensland, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Western Health Sunshine Hospital

    St Albans, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Fudan University Shanghai Cancer Centerpudong

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.